RxDoctor Payments Data

Caitlin Branham, APRN

Psychiatric/Mental Health · Mount Pleasant, TXNPI 1487167979

Payments from drug & device makers

$1,109in general payments, 2019–2025

Across 59 payments — averaging $18.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$521
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$383
  • Otsuka America Pharmaceutical, Inc.$150
  • Alkermes, Inc.$19
  • Johnson & Johnson$18
  • Vanda Pharmaceuticals Inc.$18

What the payments were for

  • Food & beverage$1,109100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,109 in reported general payments places this provider in the 60th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$45,577
Medicare patients
41
Services billed
506

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl30$42,775
Invega SustennaPaliperidone Palmitate12$25,748
Clonazepam84$824
Duloxetine Hcl53$768
Quetiapine Fumarate28$709
Buspirone Hcl41$686
Aripiprazole41$639
Venlafaxine Hcl ErVenlafaxine Hcl20$583
Bupropion XlBupropion Hcl27$527
Doxepin Hcl12$394
Sertraline Hcl27$358
Escitalopram Oxalate27$248
Alprazolam44$244
Mirtazapine28$191
Trazodone Hcl36$176

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$521$42,77530 claims
Johnson & JohnsonInvega Sustenna$18$25,74812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Mount Pleasant

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →